Press release
Alex Therapeutics Completes Sale of Levilog to Navamedic
Alex Therapeutics has completed the sale of Levilog, its software-as-a-medical-device (SaMD) application for Parkinson's disease management, to Navamedic (OSE: NAVA).Levilog was developed by Alex Therapeutics in close collaboration with Navamedic to support people living with Parkinson's disease who require complex and individualized treatment regimens. The application provides a range of digital tools for treatment management, including medication reminders, treatment logging, and symptom tracking, helping patients manage the day-to-day challenges associated with Parkinson's disease and stay engaged with their care between appointments.
Since its launch, Levilog has been made available across Nordic markets as part of a broader effort to complement existing Parkinson's disease treatment pathways with digital support. The application was designed to support patients prescribed advanced Parkinson's therapies and to facilitate treatment adherence and self-management between clinical visits, giving patients better visibility into the progression of the condition over time.
The sale marks the successful culmination of Alex Therapeutics' work bringing Levilog from concept to market, spanning regulatory approvals, market launches, and close collaboration with healthcare professionals, patient communities, and industry partners. Throughout this journey, the goal remained constant: to deliver meaningful, evidence-based digital support to people living with Parkinson's disease. With Levilog now positioned for its next chapter under Navamedic, a dedicated partner with deep roots in the field, Alex Therapeutics is proud to have built a product that meaningfully supports patients and to know it will continue to serve them well into the future.
Alex Therapeutics AB
Kungsgatan 64, 11122 Stockholm
press@alextherapeutics.com
Alex Therapeutics is a digital health company based in Stockholm that partners with pharmaceutical companies to support people with treatment and disease-related mental health challenges through clinically validated companion apps. For more information, visit: www.alextherapeutics.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alex Therapeutics Completes Sale of Levilog to Navamedic here
News-ID: 4562049 • Views: …
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
QualitySolicitors Parkinson Wright invest in the future
QualitySolicitors Parkinson Wright has selected Liberate from Linetime as its business-wide legal services software platform. The Worcestershire based practice, with over 100 staff, operate from 4 offices and have a highly regarded reputation for their services including residential property, private client, family, dispute resolution and commercial. The firm also has its own estate agency.
The firm recognised that to continue delivering high quality services to its clients it needed to provide…
